Home Blog Page 8

Robo.ai Inc. Announces Appointment of Wang Hao, Senior Executive Officer of UAE Independent Digital Asset Custodian Changer.ae, as Independent Director

By
Advertorial Desk
-

ABU DHABI, UAE, Aug. 21, 2026 /PRNewswire/ — Robo.ai Inc. (Nasdaq: AIIO) (the “Company” or “Robo.ai”), a UAE-based Nasdaq-listed company, today announced the appointment of Mr. Hao Wang as an independent director of the Company’s board of directors (the “Board”), effective immediately. Mr. Wang also will serve as a member of the Board’s Audit Committee, Compensation Committee, and Strategy and ESG Committee. The Board has determined that Mr. Wang satisfies the independence requirements under the applicable Nasdaq listing rules and the rules of the U.S. Securities and Exchange Commission (the “SEC”).

Mr. Wang brings 20 years of experience across finance and technology, with expertise spanning blockchain, asset tokenization, family offices, global macro hedge funds, and investment banking. He currently serves as senior executive officer of Changer.ae. He previously served as chief operating officer of SGTOX, a digital asset platform established in Singapore, and as chief operating officer of MetaBank, where he developed blockchain-based technology solutions for developing countries. Prior to that, he held key roles at IDEG Singapore and its affiliated firms, where he led the establishment of the group’s global headquarters in Singapore and the acquisition of its fund management license. His earlier investment banking experience includes positions at Citi and Nomura.

Mr. Wang has been a CFA charterholder since 2010 and is a Chartered Fellow of the Global FinTech Institute. He is an investor in Multicoin Capital, Spartan, LongHash Ventures, and Blockchain Founders Fund. Trilingual in English, Mandarin, and Japanese, he holds degrees in materials engineering from Tsinghua University and the University of Tokyo.

The Board of Robo.ai commented: “Mr. Wang brings two decades of experience across institutional finance, digital assets, and asset tokenization. His background is directly relevant to Robo.ai’s intelligent infrastructure strategy, and his appointment strengthens the independence and professional depth of the Board.”

Mr. Wang commented: “Robo.ai is building intelligent infrastructure across artificial intelligence, robotics and mobility, advanced manufacturing, and digital assets and capital. I look forward to working with the Board to support the Company’s governance and long-term development.” Mr. Wang succeeds Mr. Yehong Ji, who has resigned from the Board and its committees effective August 11, 2026 and has confirmed that his resignation does not result from any dispute or disagreement with the Board or the Company.

About Robo.ai Inc.

Robo.ai Inc. (Nasdaq: AIIO) is a technology group building intelligent infrastructure across four platforms: artificial intelligence, robotics and mobility, advanced manufacturing, and digital assets and capital. Its industrial group, Alif Holding, is dedicated to building intelligent industries through the development, integration and manufacturing of AI systems, serving government, public-sector, and mission-critical domains. Its subsidiary Neurovia AI develops AI software and visual data infrastructure. Its capital platform, Quantum Core Capital, operates as an AI-powered deep-tech holding and venture-building platform, incubating, investing in and operating technology companies. The company is headquartered in Abu Dhabi, with regional centres in Tokyo, Singapore, and New York.

Forward-Looking Statements

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “targets,” “likely to,” “challenges,” and similar statements. Robo.ai may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including statements about Robo.ai’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Robo.ai’s strategies, future business development, and financial condition and results of operations; Robo.ai’s limited operating history in its current business; Robo.ai’s ability to generate positive cash flow and profits; Robo.ai’s ability to compete successfully; Robo.ai’s ability to build its brand and withstand negative publicity; and changes in customer demand and government incentives, subsidies, or other favorable government policies. Further information regarding these and other risks is included in Robo.ai’s filings with the SEC. All information provided in this press release is as of the date of this press release, and Robo.ai does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

TDCX Opens Second Hyderabad Campus, Reinforcing India as Key Global Delivery Hub

By
Advertorial Desk
-

New Meenakshi Eco Park campus supports a more than 600% increase in TDCX’s India headcount over three years, reinforcing the country’s role in serving global technology and digital economy clients

HYDERABAD, INDIA – Media OutReach Newswire – 21 August 2026 – TDCX, a leading global customer experience solutions firm, today opened its second campus in India at Meenakshi Eco Park in Hyderabad. The new site reinforces India’s position as the company’s fourth-largest operations base and follows a more than 600% increase in TDCX’s India headcount over the past three years.

TDCX Founder and CEO Laurent Junique (center) cuts the ribbon at the company's second Hyderabad campus at Meenakshi Eco Park, joined by Group CIO and EVP Byron Fernandez and India Country Director Ananth Premkumar, August 20, 2026.
TDCX Founder and CEO Laurent Junique (center) cuts the ribbon at the company’s second Hyderabad campus at Meenakshi Eco Park, joined by Group CIO and EVP Byron Fernandez and India Country Director Ananth Premkumar, August 20, 2026.

Hyderabad is one of TDCX’s fastest-growing locations, supported by the city’s strong technology ecosystem, deep talent pool, and growing reputation as a center for customer experience, sales, digital support, and technology-enabled services.

The India Business Process Outsourcing services market, valued at approximately US$18.7 billion in 2024, is projected to reach US$51 billion by 2035 (Market Research Future, India Business Process Outsourcing Services Market, April 2026). TDCX has outpaced this market as global clients consolidate complex customer, sales, and technology workflows with fewer, more capable partners.

Byron Fernandez, Group Chief Information Officer and EVP, TDCX, with executive oversight of the company’s India operations, said: “India has moved well past the cost arbitrage conversation. When clients choose Hyderabad for customer experience, sales, or technology support, they are choosing access to skilled, ambitious talent that can run complex workflows at scale. Our expansion here reflects how seriously global clients now take India as a primary delivery market, rather than a secondary one.”

A campus built for scale and speed
Located within the 6 million sq. ft. Meenakshi Eco Park, one of Hyderabad’s key technology corridors, the new campus is designed to support TDCX’s continued expansion in India while giving employees a workplace built around learning, collaboration, and performance.

TDCX India supports leading global brands across digital advertising, e-commerce, fintech and technology, delivering omnichannel support for clients across Australia, New Zealand, the United Kingdom, Ireland, and North America. TDCX India has achieved strong customer and business outcomes for global clients, achieving high customer satisfaction scores while supporting complex workstreams across multiple markets reflecting the strength of its delivery model and the quality of talent in the market.

Ananth Premkumar, Country Director, TDCX India, said: “Hyderabad has emerged as one of India’s leading hubs for technology, innovation, and customer experience delivery. As our clients expand across global markets, they need partners who can quickly build high-quality teams at scale. For one of our technology clients, we are able to make agents production-ready in under six weeks, helping them accelerate their go-to-market timelines. This combination of skilled talent, speed, and operational excellence is what makes Hyderabad such a strategic location for TDCX.”

Recognized as a Great Place to Work for four consecutive years, TDCX India continues to build its reputation as both a strong delivery hub and an employer of choice.

Hashtag: #TDCX #CX #Outsourcing #EnableTheFuture

The issuer is solely responsible for the content of this announcement.

About TDCX

Singapore-headquartered TDCX is a leading global customer experience solutions firm that provides customer experience solutions, sales and digital marketing services, and content moderation for clients across industries including digital advertising and social media, e-commerce, fintech, gaming, healthtech, media, technology, and travel and hospitality.
With a focus on helping companies enable the future, TDCX’s smart, scalable approach, driven by innovation and operational precision, positions it as a key partner for companies targeting tangible outcomes. With more than 20,000 employees across 37 locations worldwide, TDCX provides clients with comprehensive coverage in Asia, Europe, and the Americas.

For more information, please visit .

Trina Storage and Uzmetkombinat Explore Industrial Battery Storage Cooperation in Uzbekistan

By
Advertorial Desk
-

CHUZHOU, China, Aug. 21, 2026 /PRNewswire/ — Trina Storage, the energy storage business unit of Trinasolar, recently welcomed a delegation from Uzmetkombinat JSC to its manufacturing base in Chuzhou, China. Organized by All Solar, Trinasolar’s module distributor in Uzbekistan, the visit focused on how battery energy storage systems (BESS) could support Uzmetkombinat’s industrial energy requirements.

Trina Storage and Uzmetkombinat representatives during the delegation visit to Trinasolar’s manufacturing base in Chuzhou, China
Trina Storage and Uzmetkombinat representatives during the delegation visit to Trinasolar’s manufacturing base in Chuzhou, China

Based in Bekabad, Uzmetkombinat is an established Uzbek metallurgical producer of rolled steel, grinding steel balls, ferroalloys and other industrial products. Its delegation toured Trina Storage’s manufacturing and system integration facilities and discussed using BESS to optimize electricity loads, reduce peak demand, improve energy efficiency and strengthen power supply stability.

Trina Storage introduced its vertically integrated cell-to-system capabilities, built around in-house manufactured lithium iron phosphate cells. The platform integrates the battery management system, power conversion system, energy management system, liquid cooling and fire protection. The delegation also learned about Elementa 3, Trina Storage’s latest utility-scale BESS, which uses an in-house 587 Ah cell and provides up to 6.25 MWh of storage capacity per container. Its multilayer safety architecture includes millisecond-level early warning, UL94-5VA flammability-rated modules and composite walls providing two hours of fire resistance.

Uzmetkombinat delegation touring Trina Storage’s manufacturing and system integration facilities in Chuzhou, China
Uzmetkombinat delegation touring Trina Storage’s manufacturing and system integration facilities in Chuzhou, China

This combination of in-house technology, safety engineering and system integration is supported by Trinasolar’s inclusion in S&P Global Energy’s 2026 Tier 1 Cleantech Companies List for both photovoltaic modules and energy storage systems. Trina Storage has also secured BloombergNEF Tier 1 energy storage supplier status for ten consecutive quarters, reinforcing its international bankability and delivery credentials.

Abdullaev Bakhodir Tojimirzaevich, Chairman of the Management Board – General Director of JSC “Uzmetkombinat” said, “Uzmetkombinat is continuing to modernize its operations with a focus on energy efficiency, sustainable development and the responsible use of resources. Battery energy storage is an area we are interested in exploring as we look at ways to manage energy more effectively, strengthen operational reliability and support our longer-term decarbonization objectives.”

Following the visit, Trina Storage and Uzmetkombinat will continue discussions on the potential application of battery energy storage within Uzmetkombinat’s operations.

Ku Junheong, Vice President of Trinasolar Asia Pacific, said: “Energy-intensive industries have an important role to play in Uzbekistan’s energy transition. Battery storage can provide greater flexibility in how electricity is managed and, alongside renewable generation, support more efficient and reliable industrial energy systems. We see our engagement with Uzmetkombinat as an opportunity to apply Trina Storage’s technology and system expertise to these evolving requirements.”

This potential cooperation sits within a broader national push to provide flexible, reliable and more efficient energy solutions for Uzbekistan’s industrial sector. The discussions come as Uzbekistan accelerates energy storage deployment, with national plans calling for 4.5 GW of storage capacity by 2030.

Singapore parent develops AI oral examiner for PSLE students as AI becomes part of exam preparation

By
Advertorial Desk
-

Built by a Singapore parent, the platform uses real-time AI conversation and parent-shared prelim themes to help students practise before the PSLE oral examinations.


SINGAPORE – Media OutReach Newswire – 21 August 2026 – Articulate Intelligence has launched updated PSLE English and Chinese oral examination practice tools on its AI learning platform, giving students a way to rehearse live oral conversations at home before the national examinations.

The launch comes as AI use becomes increasingly common among primary-school-aged children. National studies found that 82.6 per cent of Singaporean children aged 10 to 13 had used AI tools. With many PSLE candidates already familiar with the technology, the more relevant question is how it supports their learning—whether it simply supplies answers or helps them think and respond independently. This distinction is particularly important in oral examinations, where students must listen, formulate their own responses, elaborate and handle follow-up questions in real time.

Articulate Intelligence’s AI Oral Examiner is designed around that real-time pressure. Students first choose English or Chinese, then select a topic from a dropdown menu. The AI examiner then speaks with the student, listens to the answer, and asks follow-up questions based on what was said. If a student freezes, the system can prompt them to expand their answer, but it does not simply hand over a model response.

Ahead of the PSLE oral examinations, the platform has also added practice topics shaped by parent-shared prelim experiences. Parents shared topics their children had encountered, which Articulate Intelligence distilled into broader themes with generated images and questions for students to practise on the platform.

The platform was created by Meng Aun Tan, Founder of Articulate Intelligence, after he struggled to help his own daughter prepare for PSLE oral examinations in 2024. He later shared an early version with parents from a school volunteer group and found that many faced the same difficulty. Today, Articulate Intelligence has close to 500 users, according to company figures, with usage rising around major examination periods.

“Oral exams are not just about knowing a good answer. Students need to think while someone is waiting, respond clearly, and keep going when they are unsure,” said Meng Aun Tan, Founder, Articulate Intelligence. “I built this first for my own children because I realised that, as a parent, I could not always give useful oral exam feedback on the spot. The AI should not replace teachers or parents, but it should give students more chances to practise, so that when they meet a real examiner, the experience feels less frightening.”

The first topic is available free for users. Other topics require paid credits or a subscription. Beyond PSLE English and Chinese oral practice, Articulate Intelligence also offers AI tools for composition grading, situational writing feedback, O-Level English oral practice, and DSA interview preparation.

Parents, schools, and tuition centres can try the platform or make enquiries at (https://articulate.com.sg).

Hashtag: #articulateintelligence #PSLE #psletraining

The issuer is solely responsible for the content of this announcement.

About Articulate Intelligence

Articulate Intelligence develops AI-powered education tools for parents, students, schools, and tuition centres. Its platform includes a real-time AI Oral Examiner for English and Chinese oral practice, as well as AI graders for composition and situational writing. Founded by Singapore parent Meng Aun Tan, the company focuses on making personalised practice more accessible while supporting, not replacing, teachers and parents. Learn more at ().

Laos Cuts 7-Day Base Interest Rate to 7% as Economic Risks Persist

By
Phoudasack Vongsay
-
A picture of Lao Kip used for illustration purpose only.

The Bank of Laos (BOL) has cut its seven-day base interest rate from 8 percent to 7 percent a year as inflation remains below the government’s 8 percent target.

The Monetary Policy Committee approved the cut at its meeting on 20 August, where it reviewed monetary policy, economic conditions, fuel prices, exchange rates and financial stability.

According to BOL, the latest decision shows continued monetary stability, with inflation remaining close to the government’s target, while the exchange rate and money supply remained within planned levels.

Inflation fell from 10.2 percent in April to 7.4 percent in June as lower fuel and transport costs and a more stable exchange rate eased pressure on consumers. But inflation edged up to 7.6 percent in July, driven mainly by surging electricity costs and continued pressure from high transport, fuel, and service prices.

Policy, Ongoing Economic Risks 

The BOL will also extend foreign exchange market operating hours by one hour, from 9 AM to 4 PM.

Despite easing inflation,the central bank warned of several risks to economic stability, including slower global growth, volatile gold and oil prices, and political uncertainty in the Middle East.

Domestic challenges also remain. High demand for foreign currency to service debt, continued use of multiple currencies and other structural weaknesses are limiting the effectiveness of monetary policy, according to the BOL.

The central bank said it will continue using a mixed monetary policy approach, including tighter foreign exchange management, centralizing government deposits, improving payment systems and coordinating with other sectors on fuel supplies, imports and economic stability.

Previous Changes

The latest decision extends a series of cuts to the BOL’s seven-day base rate over the past year.

In August 2025, the central bank cut the rate from 9.5 percent to 9 percent, followed by another reduction to 8.5 percent in November 2025 as it sought to support liquidity and credit growth amid global uncertainty, exchange-rate fluctuations and weak domestic lending.

The rate was later cut to 8 percent in 2026. The BOL kept it at that level in May before reducing it again this week.

Laos Gives Unlicensed Beauty Clinics Until November to Obtain Permits Amid Weak Oversight Concerns

By
Thongsavanh Souvannasane
-
This photo is used for representational purpose only.

The Ministry of Health has ordered unlicensed medical and beauty facilities across Laos to obtain official permits by 30 November, but the directive has raised questions over its delayed public release and how authorities will enforce the deadline.

The Ministry issued the directive on 29 May but did not publicize it until 17 August, nearly three months later.

The notice targets a broad range of unlicensed facilities, including medical and dental clinics, plastic surgery centers, beauty centers and stem cell facilities. It says many currently operate without valid medical practice licenses, fail to meet technical standards or use misleading advertising that could endanger public health.

The directive cites the Law on Medical Treatment and covers procedures including surgery, injections, liposuction, piercing, acupuncture and stem cell treatments.

Operators already providing unlicensed services must submit documents to their provincial health department or the Vientiane Capital Health Department between 1 June and 30 November. New businesses must apply through district or provincial health offices and complete the required approval process before operating.

Questions Over Enforcement

The directive has generally received a positive response from the public, with some commenters welcoming tighter regulation of the sector.

“What a great move! This regulation should have been implemented so long ago,” one commenter wrote.

But the notice leaves several questions about enforcement unanswered.

It does not specify penalties for operators that fail to obtain a license by 30 November, such as fines, equipment confiscation, closure or criminal charges. It also does not explain what action authorities will take against clinics that continue operating without licenses after the deadline.

The timing of the announcement has also drawn criticism.

“Why do you post this so late?” one commenter asked. Another wrote, “This should have been done a long time ago; it is extremely dangerous.”

The six-month registration period also raises questions about whether unlicensed clinics can continue offering higher-risk procedures while they seek approval. The directive does not say whether facilities performing surgery, injections or other potentially dangerous treatments must suspend those services during the registration period.

Nor does it clarify whether health authorities will conduct inspections while operators are applying for licenses.

The Ministry also has not said whether it will publish a list of licensed facilities, which could help patients identify clinics that have met the required standards.

The directive marks a step toward tighter oversight of Laos’ growing medical and beauty sector, but clearer information on inspections, patient protection and enforcement could determine how effectively the new requirements are put into practice.

Objective Digital Psychological Assessment Launches in Singapore, Offering Clarity for Inattention and Hyperactivity Concerns

By
Advertorial Desk
-
SINGAPORE – Media OutReach Newswire – 21 August 2026 – A new, scientifically proven digital assessment service is now available in Singapore, offering an objective window into psychological brain function for individuals struggling with inattention, hyperactivity and depression. Powered by the pioneering research of leading psychological scientists, the Digital Psychological Assessment continues to be conducted at iHealthtech NUS and is administered by www.objectiveADHDassessment.sg. The research team is translating years of cutting-edge research into a practical solution for the public.

For the first time, people in Asia can access a multimodal, objective assessment that moves beyond subjective questionnaires and interviews. The service leverages functional near-infrared spectroscopy (fNIRS), a non-invasive and painless technology that uses weak, harmless near-infrared light to measure brain activity in the frontal and temporal lobes. This is the same technology developed and validated by a team of psychological scientists whose work has been published in academic journals, including this publication and this publication, and featured in The Straits Times.

The principal investigator, who ranks among the world’s top 1–2% most highly cited psychological scientists, developed this approach to bring objective measurement to human functioning. The technology measures oxygen levels in the brain’s frontal and temporal lobes during cognitive tasks. Combined with eye-tracking and continuous performance tests, it provides a comprehensive and objective picture of inattention and hyperactivity.

This service is invaluable for parents concerned about their child’s inattention and hyperactivity, young adults, and working professionals who have long suspected neurodivergent difficulties but have lacked clear answers. By providing measurable biomarker data, the assessment helps people understand their own brain function, leading to more targeted support and interventions.

“This field often involves assessment without objective tools,” some scientists have stated, drawing a parallel to a simple test that provides a clear indication. This breakthrough offers a definitive, data-backed path towards understanding and managing one’s challenges.

The objective assessment represents a significant step forward in psychological assessment in Asia and has the potential to be extended to children and adults globally. For many, it marks the end of a long, uncertain struggle and the beginning of a clear, science-backed journey towards greater clarity and understanding.

Hashtag: #ObjectiveADHDassessment

The issuer is solely responsible for the content of this announcement.

About www.objectiveADHDassessment.sg (Singapore)

The entity is dedicated to translating research findings into real-life applications, focusing on objective, state-of-the-art psychological multimodal assessments for children and adults, leveraging technology validated by leading experts from renowned local and overseas universities.

Akeso’s AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline

By
Advertorial Desk
-

HONG KONG, Aug. 21, 2026 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA). The clearance allows initiation of a Phase I study in patients with advanced malignant solid tumors. Development of AK157D1 in combination with Akeso’s proprietary bispecific antibodies ivonescimab and cadonilimab is also planned.

AK157D1 is the third next-generation ADC candidate from Akeso to enter clinical development, following AK146D1 (TROP2/Nectin-4 ADC) and AK138D1 (HER3 ADC). The clearance further advances the Company’s IO2.0 + ADC2.0 strategy and expands its broad innovative oncology pipeline.

B7-H3 is highly expressed in a broad range of solid tumors, including non-small cell lung cancer, small cell lung cancer, prostate cancer, esophageal cancer, nasopharyngeal carcinoma, colorectal cancer, breast cancer, and glioblastoma, with limited expression in normal tissues. This profile supports its potential as a broad-spectrum antitumor target.

AK157D1 was developed entirely in-house and incorporates a proprietary design. In preclinical studies, it has shown potent antitumor activity together with a favorable safety profile. These attributes may help address certain limitations associated with existing ADCs, including hematologic toxicity and interstitial lung disease, and support its continued development as a potential ADC of choice in both mono or combination therapies.

Akeso is advancing its IO2.0 + ADC2.0 strategy, built on proprietary bispecific and multispecific antibody technology and centered on cornerstone IO2.0 assets including ivonescimab and cadonilimab. Through this approach, the company is elevating treatment standards for major cancers worldwide and building a broad oncology portfolio to create next-generation standard of care.

In the immuno-oncology field, Akeso has two approved bispecific antibodies for cancer treatment. The Company is actively evaluating ivonescimab and cadonilimab in combination with its proprietary next-generation ADC candidates. Increasingly, global partners recognize both ivonescimab and cadonilimab as preferred agents for combination regimens and breakthrough therapy explorations across a wide spectrum of tumor types. In the ADC space, Akeso has built a differentiated pipeline of next-generation candidates, including AK146D1 and AK138D1, which are already in clinical development, and AK157D1 and AK158D1 (a bispecific ADC), which are anticipated to enter the clinic shortly. These agents are designed to address the narrow therapeutic window and safety limitations commonly associated with first-generation ADCs.

About AK157D1

AK157D1 is a novel B7-H3-targeting ADC independently developed by Akeso. It comprises a recombinant humanized IgG1/κ monoclonal antibody site-specifically conjugated to Dxd, a camptothecin-derived topoisomerase I inhibitor, via a maleimidocaproyl-alanine-alanine-alanine (MC-AAA) linker to interchain cysteine residues. Preclinical studies have demonstrated potent antitumor activity and a favorable safety profile.

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world’s first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.

Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, 27 candidates have advanced into clinical trials—including 15 bispecific or multispecific antibodies and bispecific ADCs—and 8 innovative drugs have reached commercial stage.

Through efficient and groundbreaking R&D, Akeso integrates premier global resources to develop transformative medicines, deliver high-quality, affordable therapeutic antibodies to patients worldwide, and generate sustained commercial and societal value as it strives to become a global leader in biopharmaceutical innovation.

Forward-Looking Statements

This announcement by Akeso, Inc. (9926.HK, “Akeso”) contains “forward-looking statements”. These statements reflect the current beliefs and expectations of Akeso’s management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso’s other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

1...789...6,446Page 8 of 6,446